Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Rinaldi, Catherine ^a   Penhale, William J ^b   Stumbles, Philip A ^b   Tay, Guan ^a   Berry, Cassandra M ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL1 CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; INFECTION CONTROL; INFLUENZA A; INFLUENZA VIRUS A; INNATE IMMUNITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PROVOCATION TEST; VIRAL CLEARANCE; VIRUS LOAD; VIRUS NEUTRALIZATION; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; IMMUNITY, INNATE; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE INFECTIONS; SHEEP;

EID: 84896514973     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089674     Document Type: Article

References (58)

1. Taubenberger JK, Morens DM (2009) Pandemic influenza - including a risk assessment of H5N1. Review Scientific and Technical Office International Epizootics 28: 187-202.
2. Ahmed R, Oldstone MBA, Palese P (2007) Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nature Immunology 8: 1188-1193. (Pubitemid 350011755)
3. Kilbourne E (1987) Influenza, Plenum Medical Book Company, New Year.
4. Oxford JS, Lambkin R (2006) Influenza is now a preventable disease. International Journal of Antimicrobial Agents 27: 271-273.
5. Nguyen AM, Noymer A (2013) Influenza mortality in the United States, 2009 pandemic: burden, timing and age distribution. PLoS One 8: e64198.
6. WHO (2013) Available: http://www.who.int/influenza/human-animal- interface/EN-GIP-20131210CumulativeNumberH5N1cases.pdf?ua=1.Accessed 2014 Jan 29.
7. WHO (2013) Available: http://www.who.int/influenza/human-animal- interface/influenza-h7n9/10u-ReportWebH7N9Number.pdf?ua = 1.Accessed 2014 Jan 29.
8. Subbarao K, Murphy BR, Fauci AS (2006) Development of effective vaccines against pandemic influenza. Immunity 24: 5-9. (Pubitemid 43077193)
9. Rockman S, Maher D, Middleton D (2012) The use of hyperimmune serum for severe influenza infections. Critical Care Medicine 40: 973-975.
10. Akerfeldt S, Geijer S, Holubars E, Fuchs G, Brundin M (1972) Prophylactic and therapeutic antiviral effect of human gamma globulin. Biochemical Pharmacology 21: 503-509.
11. Ramisse F, Deramoudt FX, Szatanik M, Bianchi A, Binder P, et al. (1998) Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments. Clinical and Experimental Immunology 111: 583-587. (Pubitemid 28160905)
12. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals Internal Medicine 145: 599-609. (Pubitemid 46780940)
13. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, et al. (2010) Hark back: Passive immunotherapy for influenza and other serious infections. Critical Care Medicine 38: S1-8.
14. Hernandez E, Ramisse F, Lhonneux A, Noury J, Bazin H, et al. (2003) Compared protective effect of nasal immunoprophylaxis using new human monoclonal IgM antibody, human polyclonal antibodies, F(ab')2, amantadine and zanamivir for prophylaxis of influenza A virus pneumonia in mice. Military Medicine 168: 246-251. (Pubitemid 36331734)
15. Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, et al. (2009) Pre- and postexposure use of human monoclonal antibody against H5N1 an H1N1 influenza virus in mice: viable alternative to oseltamivir. Journal of Infectious Diseases 200: 1870-1873.
16. Wang R, Song A, Levin J, Dennis D, Zhang NJ, et al. (2008) Therapeutic potential of fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Research 80: 168-177.
17. Wang TT, Palese P (2009) Universal epitopes of influenza virus hemagglutinins? Nature Structural Molecular Biology 16: 233-234.
18. Kris RM, Yetter RA, Cogliano R, Ramphal R, Small PA (1988) Passive serum antibody causes temporary recovery from influenza virus infection of the nose, trachea and lung of nude mice. Immunology 63: 349-53.
19. Wong JP, Stadnyk LL, Saravolac EG (1994) Enhanced protection against respiratory influenza A infection in mice by liposome-encapsulated antibody. Immunology 81: 280-284. (Pubitemid 24223206)
20. Dreffier C, Ramisse F, Dubernet C (2003) Pulmonary administration of IgG loaded liposomes for passive immunoprophylaxy. International Journal of Pharmaceutics 254: 43-47. (Pubitemid 36259808)
21. Mancini N, Solforosi L, Clementi N, De Marco D, Clementi M, et al. (2011) A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Research 92: 15-26.
22. Ng W, Wong V, Muller B, Rawlin G, Brown LE (2010) Prevention and treatment of influenza with hyperimmune bovine colostrum antibody. PLoS One 5: e13622.
23. Snelgrove RJ, Godlee A, Hussell T (2011) Airway immune homeostasis and implications for influenza-induced inflammation. Trends in Immunology 32: 328-334.
24. Peiris JSM, Hui KPY, Yen HL (2010) Host response to influenza virus: protection versus immunopathology. Current Opinion in Immunology 22: 475-481.
25. Seo SU, Kwon HJ, Ko HJ, Byun YH, Seong BL, et al. (2011) Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathogen 7:e1001304.
26. Peiris JSM, Cheung CY, Leung CYH, Nicholls JM (2009) Innate immune responses to influenza A H5N1: friend or foe? Trends in Immunology 30: 574-584.
27. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, et al. (2011) Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146: 980-991.
28. Taubenberger JK, Morens DM (2006) 1918 influenza: the mother of all pandemics. Emerging Infectious Diseases 12: 15-22. (Pubitemid 43143529)
29. Johansson BE, Bucher DJ, Kilbourne ED (1989) Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. Journal of Virology 63: 1239-1246. (Pubitemid 19061366)
30. World Organisation for Animal Health (2004) Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Volume 1. Chapter 2.1.14. Available: http://www.oie.int/doc/ged/D6460.PDF. Accessed 2014 Jan 29.
31. Van Deusen RA, Hinshaw VS, Senne DA, Pellacani D (1983) Micro neuraminidase-inhibition assay for classification of influenza A virus neuraminidases. Avian Diseases 27: 745-750.
32. Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, et al. (1973) Influenza neuraminidase and neuraminidase-inhibition test procedures. Bulletin of World Health Organisation 48: 199-202.
33. Tang JW, Ngai LK, Chan PKS (2008) Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans. Journal of Medical Virology 80: 1992-1996.
34. James CM, Abdad MY, Mansfield JP, Jacobsen HK, Rezazadeh Vind A, et al. (2007) Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 25: 1856-1867. (Pubitemid 46176322)
35. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. American Journal of Hygiene 27: 493-497.
36. Cull VS, Bartlett EJ, James CM (2002) Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology 106: 428-37. (Pubitemid 34748138)
37. Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, et al. (2012) A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidaseinhibiting antibodies. Journal of Infectious Diseases 205: 28-34.
38. Hu AYC, Tseng YF, Weng TC, Liao CC, Wu J, et al. (2011) Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS One 6: e14578.
39. Papenburg J, Baz M, Hamelin MEÉ , Rhéaume C, Carbonneau J, et al. (2011) Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clinical and Vaccine Immunology 18: 520-522.
40. Lingwood D, McTamney PM, Yassine HM, Whittle JR, Guo X, et al. (2012) Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489: 566-570.
41. Meng W, Pan W, Zhang AJ, Li Z, Wei G, et al. (2013) Rapid generation of human-like neutralizing monoclonal antibodies in urgent preparedness for influenza pandemics and virulent infectious diseases. PLoS One 8: e66276.
42. Pestka S (2007) The interferons: 50 years after their discovery, there is much more to learn. Journal of Biological Chemistry 282: 20047-20051 (Pubitemid 47099975)
43. Garcia-Sastre A, Durbin RK, Zheng H, Palese P, Gertner R, et al. (1998) The role of interferon in influenza virus tissue tropism. Journal of Virology 72: 8550-8558. (Pubitemid 28471792)
44. Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, et al. (2009) Early control of H5N1 influenza virus replication by type I interferon response in mice. Journal of Virology 83: 5825-5834.
45. Berry CM, Hertzog PJ, Mangan NE (2012) Interferons as biomarkers and effectors: lessons learned from animal models. Biomarkers in Medicine 6: 159-176.
46. Gefen T, Pitcovski J, Vaya J, Khatib S, Krispel S, et al. (2010) Coated crossspecies antibodies by mannosamine-biotin adduct confer protection against snake venom without eliciting humoral immune response. Vaccine 28: 8197-8202.
47. Alisky J (2009) Bovine and human-derived passive immunization could help slow a future avian influenza pandemic. Medical Hypotheses 72: 74-75.
48. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, et al. (1998) Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. The Journal of Clinical Investigation 101: 643-649. (Pubitemid 28084248)
49. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H (2003) Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21: 3212-3218. (Pubitemid 36700428)
50. James CM, Foong YY, Mansfield JP, Fenwick SG, Ellis TM (2007) Use of tetanus toxoid as a differentiating infected from vaccinated animals (DIVA) strategy for sero-surveillance of avian influenza virus vaccination in poultry. Vaccine 25: 5892-5901. (Pubitemid 47043219)
51. Hovden AO, Cox RJ, Haaheim LR (2005) Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scandinavian Journal of Immunology 62: 36-44. (Pubitemid 41025876)
52. Brett IC, Johansson BE (2005) Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339: 273-280. (Pubitemid 41169794)
53. Tate MD, Ioannidis LJ, Croker B, Brown LE, Brooks AG, et al. (2011) The role of neutrophils during mild and severe influenza virus infections of mice. PLoS One 6: e17618.
54. Brandes M, Klauschen K, Kuchen S, Germain RN (2013) A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell 154: 197-212.
55. Ye J, Shao H, Hickman D, Angel M, Xu K, et al. (2010) Intranasal delivery of an IgA monoclonal antibody effective against a sublethal H5N1 influenza virus infection in mice. Clinical and Vaccine Immunology 17: 1363-1370.
56. Ye J, Shao H, Perez DR (2012) Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy 4: 175-186.
57. Girard MP, Cherian T, Pervikov Y, Kieny MP (2005) A review of vaccine research and development: human acute respiratory infections. Vaccine 23: 5708-5724. (Pubitemid 41668877)
58. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. New England Journal of Medicine 357: 1450-1451. (Pubitemid 47535608)